natgillin/translations-raw huggingface dataset:
The amlodipine component of Copalia HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. 
Amlodipin v zdravilu Copalia HCT zavira transmembranski vstop kalcijevih ionov v srčne in žilne gladke mišice.
What you need to know before you take Copalia HCT 
Kaj morate vedeti, preden boste vzeli zdravilo Copalia HCT
How to store Copalia HCT Contents of the pack and other information 
Shranjevanje zdravila Copalia HCT Vsebina pakiranja in dodatne informacije
• severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions 
• hude kožne reakcije, vključno s hudim kožnim izpuščajem, koprivnico, pordelostjo kože po celem telesu, močnim srbenjem, pojavljanjem mehurjev, lupljenjem in otekanjem kože, vnetjem sluznic (Stevens-Johnsonov sindrom, toksična epidermalna nekroliza) in drugimi alergijskimi reakcijami
The use of Copalia HCT during breastfeeding is not recommended. 
Uporaba zdravila Copalia HCT med dojenjem ni priporočena.
What Copalia HCT is and what it is used for What you need to know before you take Copalia HCT How to take Copalia HCT 
Kaj je zdravilo Copalia HCT in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Copalia HCT Kako jemati zdravilo Copalia HCT Možni neželeni učinki
In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Copalia HCT. 
Pri bolnikih s primanjkljajem natrija in/ali hipovolemijo, na primer pri bolnikih, ki prejemajo visoke odmerke diuretikov, se lahko po uvedbi zdravljenja z zdravilom Copalia HCT pojavi simptomatska hipotenzija.
In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Copalia HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Copalia HCT for clinical use in humans. 
V različnih predkliničnih študijah varnosti zdravila, ki so jih izvajali na več živalskih vrstah z amlodipinom, valsartanom in hidroklorotiazidom ter s kombinacijami valsartan/hidroklorotiazid, amlodipin/valsartan in amlodipin/valsartan/hidroklorotiazid (z zdravilom Copalia HCT), ni bilo znakov za sistemsko toksično delovanje ali toksično delovanje na tarčne organe, ki bi predstavljali razloge proti razvijanju zdravila Copalia HCT za klinično uporabo pri ljudeh.
The full blood pressure lowering effect was achieved 2 weeks after being on their maximal dose of Copalia HCT. 
Do polnega učinka na zniževanje krvnega tlaka je prišlo po 2 tednih zdravljenja z najvišjimi odmerki zdravila Copalia HCT.
Based on the existing data with the components, the use of Copalia HCT is not recommended during first trimester and contraindicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4). 
Glede na obstoječe podatke o posameznih sestavinah uporaba zdravila Copalia HCT ni priporočljiva v prvem trimesečju nosečnosti in je kontraindicirana v drugem in tretjem trimesečju nosečnosti (glejte poglavji 4.3 in 4.4).
You can take Copalia HCT with or without food. 
Zdravilo Copalia HCT lahko vzamete s hrano ali brez nje.
In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Copalia HCT were dizziness and hypotension (0.7%). 
V tem aktivno kontroliranem kliničnem preskušanju sta bila najbolj pogosta razloga za prekinitev zdravljenja z zdravilom Copalia HCT omotičnost in hipotenzija
Clinically significant hypotension due to Copalia HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. 
Klinično značilna hipotenzija zaradi prevelikega odmerka zdravila Copalia HCT zahteva srčnožilno podporo, vključno s pogostim nadziranjem delovanja srca in dihal, dviganjem udov ter kontrolo krožečega volumna tekočine in izločanja urina.
Copalia HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. 
Zdravilo Copalia HCT je kontraindicirano pri bolnikih s hiperkalciemijo in ga je mogoče uporabljati šele po korekciji morebitne že prisotne hiperkalciemije.
Furthermore, concomitant use of Copalia HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. 
Poleg tega lahko sočasna uporaba zdravila Copalia HCT in NSAIDs povzroča poslabšanje delovanja ledvic in zvišanje koncentracije kalija v serumu.
Elderly patients, particularly those taking the maximum dose of Copalia HCT (10 mg/320 mg/25 mg), should have their blood pressure checked regularly. 
Starejšim bolnikom, zlasti tistim, ki uporabljajo najvišji odmerek zdravila Copalia HCT (10 mg/320 mg/25 mg), je treba redno meriti krvni tlak.
If photosensitivity reaction occurs during treatment with Copalia HCT, it is recommended to stop the treatment. 
Če med zdravljenjem z zdravilom Copalia HCT pride do fotosenzitivnostne reakcije, je priporočena prekinitev zdravljenja.
Statistically greater proportions of patients achieved blood pressure control (<140/90 mmHg) with Copalia HCT (71%) compared to each of the three dual combination therapies (45-54%) (p<0.0001). 
Krvni tlak je uspelo uravnati (<140/90 mmHg) statistično večjemu deležu bolnikov, ki so jemali zdravilo Copalia HCT (71 %) v primerjavi s tistimi, ki so jemali katero od treh kombinacij s po dvema zdraviloma (45-54 %) (p<0,0001).
Copalia HCT can be used by people aged 65 years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. 
Ljudje, ki so stari 65 let ali več, lahko uporabljajo zdravilo Copalia HCT v enakih odmerkih kot drugi odrasli in na povsem enak način, kot so prej jemali tri učinkovine amlodipin, valsartan in hidroklorotiazid.
If excessive hypotension occurs with Copalia HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. 
Če se med uporabo zdravila Copalia HCT pojavi čezmerna hipotenzija, je treba bolnika poleči in mu, če je potrebno, dati intravensko infuzijo fiziološke raztopine.
The safety of Copalia HCT has been evaluated at its maximum dose of 10 mg/320 mg/25 mg in one controlled short-term (8 weeks) clinical study with 2,271 patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. 
Varnost zdravila Copalia HCT so ocenjevali pri uporabi njegovega najvišjega odmerka 10 mg/320 mg/25 mg, in sicer v eni kotrolirani kratkotrajni (8-tedenski) klinični študiji z 2.271 bolniki, od katerih jih je 582 prejemalo valsartan v kombinaciji z amlodipinom in s hidroklorotiazidom.
Frequency Copalia HCT 
Pogostnost Copalia HCT
The safety profile of Copalia HCT presented below is based on clinical studies performed with Copalia HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide. 
Spodaj navedene varnostne lastnosti zdravila Copalia HCT se nanašajo na podatke iz študij z zdravilom Copalia HCT in na znane varnostne lastnosti njegovih posameznih sestavin amlodipina, valsartana in hidroklorotiazida.
Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with Copalia HCT. 
Ker tiazidi zmanjšajo ledvični očistek litija, uporaba zdravila Copalia HCT lahko predvidoma poveča toksične učinke litija.
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Copalia HCT. 
Grenivka in grenivkin sok lahko namreč povzročita zvišanje koncentracije učinkovine amlodipina v krvi, kar lahko pripelje do nepredvidljivega povečanja učinka zdravila Copalia HCT pri zniževanju krvnega tlaka.
The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Copalia HCT are the same as when administered as individual dosage forms. 
Hitrosti in obsegi absorpcije amlodipina, valsartana in hidroklorotiazida se ne razlikujejo od tistih pri odmerjanju posameznih sestavin.
Therefore, Copalia HCT is not recommended in this population. 
Iz tega razloga uporaba zdravila Copalia HCT ni priporočena pri tej skupini bolnikov.
Other medicines and Copalia HCT 
Druga zdravila in zdravilo Copalia HCT
Copalia HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. 
Zdravilo Copalia HCT vsebuje tri antihipertenzivne učinkovine s komplementarnimi mehanizmi delovanja za obvladanje krvnega tlaka pri bolnikih z esencialno hipertenzijo: amlodipin spada med zaviralce kalcijevih kanalčkov, valsartan med antagoniste angiotenzina II in hidroklorotiazid v skupino tiazidnih diuretikov.
When switching eligible elderly hypertensive patients (see section 4.1) to Copalia HCT, the lowest available dose of the amlodipine component should be used. 
Pri prehodu ustreznih starejših bolnikov s hipertezijo (glejte poglavje 4.1) na zdravilo Copalia HCT, je potrebno uporabiti najnižji razpoložljivi odmerek amlodipina.
In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Copalia HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. 
V 8-tedenski kontrolirani klinični študiji so bile pri uporabi kombinacije v zdravilu Copalia HCT spremembe vrednosti laboratorijskih parametrov majhne in v skladu s farmakološkim načinom delovanja posameznih sestavin.
Due to the hydrochlorothiazide component, Copalia HCT is contraindicated for use in patients with anuria (see section 4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) <30 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.2). 
Zaradi vsebnosti hidroklorotiazida je zdravilo Copalia HCT kontraindicirano za uporabo pri bolnikih z anurijo (glejte poglavje 4.3) in pri bolnikih s hudo okvaro ledvic (s hitrostjo glomerulne filtracije (GFR) <30 ml/min/1,73 m2) (glejte poglavja 4.3, 4.4 in 5.2).
If hypokalaemia develops during hydrochlorothiazide therapy, Copalia HCT should be discontinued until stable correction of the potassium balance. 
Če se hipokaliemija pojavi v času zdravljenja s hidroklorotiazidom, je treba uporabo zdravila Copalia HCT prekiniti, dokler ni ravnovesje kalija stabilno.
No formal interaction studies with other medicinal products have been performed with Copalia HCT. 
Formalnih študij medsebojnega delovanja zdravila Copalia HCT z drugimi zdravili niso izvedli.
The side effects reported with Copalia HCT or one of its three active substances (amlodipine, valsartan and hydrochlorothiazide) are listed below and may occur with the use of Copalia HCT. 
Neželeni učinki, o katerih so poročali pri uporabi zdravila Copalia HCT ali pri uporabi katere od treh učinkovin (amlodipina, valsartana in hidroklorotiazida), so navedeni spodaj in se lahko pojavijo pri uporabi zdravila Copalia HCT.
If Copalia HCT is used during breast-feeding, doses should be kept as low as possible. 
Če bolnica uporablja zdravilo Copalia HCT v času dojenja, naj uporablja čim nižje odmerke.
Copalia HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances. 
Zdravilo Copalia HCT uporabljamo za zdravljenje visokega krvnega tlaka pri odraslih bolnikih, pri katerih je krvni tlak že urejen, kadar jemljejo amlodipin, valsartan in hidroklorotiazid in bi jim ustrezalo jemanje ene same tablete, ki vsebuje vse tri učinkovine.
When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to Copalia HCT, the lowest available dose of the amlodipine component should be used. 
Pri prehodu ustreznih bolnikov s hipertezijo (glejte poglavje 4.1) z jetrno okvaro na zdravilo Copalia HCT, je potrebno uporabiti najnižji razpoložljivi odmerek amlodipina.
Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects. 
Tiazidi, vključno s hidroklorotiazidom, lahko zmanjšajo izločanje citotoksičnih učinkovin (npr. ciklofosfamida in metotreksata) preko ledvic in stopnjujejo njihov mielosupresiven učinek.
If you take more Copalia HCT than you should If you have accidentally taken too many Copalia HCT tablets, talk to a doctor immediately.You may require medical attention. 
Če ste vzeli večji odmerek zdravila Copalia HCT, kot bi smeli Če ste nehote vzeli preveč tablet zdravila Copalia HCT, se takoj posvetujte z zdravnikom.
In the controlled trial of Copalia HCT, the counteracting effects of valsartan 320 mg and hydrochlorothiazide 25 mg on serum potassium approximately balanced each other in many patients. 
V kontroliranem preskušanju zdravila Copalia HCT sta bila pri številnih bolnikih nasprotna učinka valsartana 320 mg in hidroklorotiazida 25 mg na koncentracijo kalija v serumu približno v ravnovesju.
Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren Clinical trial data have shown that dual blockade of the RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). 
Podatki kliničnih preskušanj so pokazali, da je dvojna blokada sistema renin-angiotenzin-aldosteron (RAAS) s hkratno uporabo zaviralcev ACE, antagonistov angiotenzinskih receptorjev ali aliskirena povezana z večjo pogostnostjo neželenih učinkov, npr. hipotenzije, hiperkaliemije in zmanjšanega delovanja ledvic (vključno z akutno odpovedjo ledvic) kot uporaba enega samega zdravila, ki deluje na RAAS (glejte poglavja 4.3, 4.4 in 5.1).
The maximum recommended dose of Copalia HCT is 10 mg/320 mg/25 mg. 
Najvišji priporočeni odmerek zdravila Copalia HCT je 10 mg/320 mg/25 mg.
If you forget to take Copalia HCT 
Če ste pozabili vzeti zdravilo Copalia HCT
if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as “water tablets”), especially if you suffer from asthma and allergies if you have been sick (vomiting or diarrhoea). 
če ste že imeli alergijsko reakcijo na druga zdravila za uravnavanje visokega krvnega tlaka ali na diuretike (skupino zdravil, ki jim pravimo tudi “tablete za odvajanje vode”), zlasti če imate astmo ali alergije; če vam je bilo slabo (bruhanje ali driska); če je v času jemanja drugih zdravil (kar vključuje tudi zaviralce angiotenzinske konvertaze) pri vas prišlo do otekanja, zlasti v obraz in grlo oziroma žrelo.
Copalia HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. 
Tablete Copalia HCT vsebujejo tri učinkovine: amlodipin, valsartan in hidroklorotiazid.
Following oral administration of Copalia HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6-8 hours, 3 hours, and 2 hours, respectively. 
Po peroralni uporabi zdravila Copalia HCT pri normalnih zdravih odraslih doseže amlodipin najvišjo koncentracijo v plazmi v 6-8 urah, valsartan v 3 urah, hidroklorotiazid pa v 2 urah.
In case severe or rapid hyponatraemia develops during Copalia HCT therapy, the treatment should be discontinued until normalisation of natraemia. 
Če se v času zdravljenja z zdravilom Copalia HCT razvije huda ali nenadna hiponatriemija, je treba zdravljenje prekiniti do normalizacije vrednosti natrija v krvi.
There are no clinical studies on fertility with Copalia HCT. 
Kliničnih študij glede plodnosti pri uporabi zdravila Copalia HCT ni.
Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25-1.52] p<0.001). 
Med sekundarnimi cilji opazovanja je bila pogostnost srčnega popuščanja (eden od izidov, ki so bili vključeni v sestavljen kardiovaskularni cilj opazovanja) statistično značilno večja v skupini z amlodipinom v primerjavi s skupino s klortalidonom (10,2 % v primerjavi s 7,7 %, z razmerjem tveganj (RR) 1,38; 95-odstotnim
If you get these symptoms, stop taking Copalia HCT and contact your doctor straight away. 
Če opazite navedene simptome, takoj prenehajte jemati zdravilo Copalia HCT in obvestite svojega zdravnika.
Do not use any Copalia HCT pack that is damaged or shows signs of tampering. 
Zdravila Copalia HCT ne uporabljajte, če je ovojnina poškodovana ali opazite, da je bila že odprta.
Due to the hydrochlorothiazide component, Copalia HCT is contraindicated in symptomatic hyperuricaemia. 
Zaradi vsebnosti hidroklorotiazida je pri bolnikih s simptomatsko hiperurikemijo uporaba zdravila Copalia HCT kontraindicirana.
When Copalia HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended. 
Pri bolnikih z okvaro ledvic, ki jemljejo zdravilo Copalia HCT, je priporočljivo periodično kontrolirati koncentracije elektrolitov v serumu (vključno s koncentracijami kalija), kreatinina in sečne kisline.
The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Copalia HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually. 
Spodaj navedeni neželeni učinki, ki so našteti po MedDRA razvrstitvi organskih sistemov in po pogostnosti, se nanašajo na zdravilo Copalia HCT (amlodipin/valsartan/hidroklorotiazid) in na amlodipin, valsartan in hidroklorotiazid posamezno.
The reductions in systolic/diastolic blood pressure with Copalia HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide. 
Znižanje sistoličnega/diastoličnega krvnega tlaka je bilo z zdravilom Copalia HCT za 7,6/5,0 mmHg večje kot s kombinacijo valsartan/hidroklorotiazid, za 6,2/3,3 mmHg večje kot s kombinacijo amlodipin/valsartan in za 8,2/5,3 mmHg večje kot s kombinacijo amlodipin/hidroklorotiazid.
Concomitant use of Copalia HCT with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1). 
Sočasna uporaba zdravila Copalia HCT in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR <60 ml/min/1,73m2) (glejte poglavji 4.5 in 5.1).
Due to the valsartan component, Copalia HCT is contraindicated in patients with severe hepatic impairment (see section 4.3). 
Zaradi vsebnosti valsartana je zdravilo Copalia HCT kontraindicirano pri bolnikih s hudo okvaro jeter (glejte poglavje 4.3).
If any of the above applies to you, do not take Copalia HCT and talk to your doctor. 
Če kaj od naštetega velja za vas, ne vzemite zdravila Copalia HCT, temveč povejte zdravniku.
There is no experience of overdose with Copalia HCT. 
Izkušenj s prevelikim odmerjanjem zdravila Copalia HCT ni.
Due to the valsartan component, Copalia HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3). 
Zaradi vsebnosti valsartana je zdravilo Copalia HCT kontraindicirano pri bolnikih z okvaro jeter (glejte poglavji 4.2 in 4.3).
Copalia HCT should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients. 
Pri bolnikih z enostransko ali obojestransko stenozo ledvične arterije oz. s stenozo v primeru solitarne ledvice je pri zdravljenju hipertenzije z zdravilom Copalia HCT potrebna previdnost, saj pri takih bolnikih lahko pride do zvišanja koncentracij sečnine v krvi in kreatinina v serumu.
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Copalia HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2). 
Pri bolnikih z blago do zmerno okvaro jeter brez holestaze je najvišji priporočeni odmerek valsartana 80 mg, zato zdravilo Copalia HCT ni primerno za to skupino bolnikov (glejte poglavja 4.2, 4.3 in 5.2).
Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation) 
Srčne bolezni palpitacije pogosti tahikardija občasni aritmije (vključno z bradikardijo, ventrikularno tahikardijo in atrijsko fibrilacijo)
Before switching to Copalia HCT patients should be controlled on stable doses of the monocomponents taken at the same time. 
Preden bolnik preide na uporabo zdravila Copalia HCT, mora biti njegov krvni tlak urejen s sočasno uporabo stabilnih odmerkov posameznih učinkovin.
At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Copalia HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide. 
Po 8 tednih je bilo povprečno znižanje sistoličnega/diastoličnega krvnega tlaka 39,7/24,7 mmHg z zdravilom Copalia HCT, 32,0/19,7 mmHg s kombinacijo valsartan/hidroklorotiazid, 33,5/21,5 mmHg s kombinacijo amlodipin/valsartan in 31,5/19,5 mmHg s kombinacijo amlodipin/ hidroklorotiazid.
There is no experience on the use of Copalia HCT in pregnant women. 
Z uporabo zdravila Copalia HCT pri nosečnicah ni nobenih izkušenj.
Stopping your treatment with Copalia HCT may cause your disease to get worse. 
Če ste prenehali jemati zdravilo Copalia HCT Če prenehate jemati zdravilo Copalia HCT, se lahko vaša bolezen poslabša.
Copalia HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely. 
Če želite dojiti, bo zdravnik za vas izbral drugo zdravilo, še posebno če je vaš otrok še novorojenček ali je bil rojen prezgodaj.
if you are taking any of the following medicines used to treat high blood pressure: an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. 
zaviralec ACE (na primer enalapril, lizinopril ali ramipril), zlasti če imate kakšne težave z ledvicami, ki so povezane s sladkorno boleznijo.
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Copalia HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2). 
Pri bolnikih z blago do zmerno okvaro jeter brez holestaze je najvišji priporočeni odmerek valsartana 80 mg, zato zdravilo Copalia HCT ni primerno za to skupino bolnikov (glejte poglavja 4.3, 4.4 in 5.2).
Treatment with Copalia HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. 
Zdravljenje z zdravilom Copalia HCT je mogoče uvesti šele po korekciji hipokaliemije in morebitne sočasne hipomagneziemije.
Copalia HCT should be used only after correction of any pre-existing sodium and/or volume depletion. 
Zdravilo Copalia HCT se sme uporabiti šele po ureditvi morebitnega že prisotnega primanjkljaja natrija in/ali hipovolemije.